US Pharma MarketingArsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-T
ArsenalBio lays off 99 staffers, its second round of cuts in a year, as it pivots from solid-tumor CAR-T to an in vivo CAR-T focus. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
Roughly a year after shedding half of its workforce, Arsenal Biosciences is trimming its headcount again by letting go of “the majority” of its staffers as a result of a pivot into in vivo CAR-T ...
Source: Endpoints News